Kenvue (NYSE:KVUE) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Kenvue (NYSE:KVUE) released its quarterly earnings data on Monday. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01, Zacks reports. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. During the same period in the previous year, the firm earned $0.28 EPS. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. Kenvue updated its FY 2025 guidance to 1.000-1.050 EPS.

Kenvue Trading Up 12.6%

NYSE KVUE opened at $16.18 on Tuesday. Kenvue has a 12 month low of $14.02 and a 12 month high of $25.17. The company has a 50-day moving average of $17.11 and a 200-day moving average of $20.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The company has a market cap of $31.06 billion, a P/E ratio of 21.87, a P/E/G ratio of 2.07 and a beta of 0.71.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be paid a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.1%. Kenvue’s dividend payout ratio is currently 112.16%.

Institutional Trading of Kenvue

A number of institutional investors have recently modified their holdings of KVUE. Alliancebernstein L.P. grew its holdings in shares of Kenvue by 115.9% during the 2nd quarter. Alliancebernstein L.P. now owns 6,438,473 shares of the company’s stock worth $134,757,000 after purchasing an additional 3,456,204 shares during the period. Scopus Asset Management L.P. purchased a new stake in shares of Kenvue during the 2nd quarter worth about $40,394,000. Canada Pension Plan Investment Board grew its holdings in shares of Kenvue by 164.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 2,694,498 shares of the company’s stock worth $56,396,000 after purchasing an additional 1,674,072 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in shares of Kenvue during the 2nd quarter worth about $22,897,000. Finally, Man Group plc grew its holdings in shares of Kenvue by 1,815.8% during the 2nd quarter. Man Group plc now owns 855,280 shares of the company’s stock worth $17,901,000 after purchasing an additional 810,636 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on KVUE. UBS Group decreased their price objective on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft set a $18.00 target price on shares of Kenvue in a research note on Friday, October 24th. Evercore ISI set a $18.00 target price on shares of Kenvue in a research note on Tuesday, October 28th. JPMorgan Chase & Co. cut their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Finally, Barclays cut their target price on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $20.17.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.